Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 4 · 57.1%High 1 · 14.3%

Regular formoterol and ICS vs same‐dose ICS

Non‐fatal serious adverse events · children and adolescents with chronic asthma

Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).

1 finding from 1 review

Inhaled steroids with and without regular formoterol for asthma: serious adverse events 2019 · Cochrane Headline outcomes only
OR 1.33 [0.71, 2.49]
10 studies · 4035 participants
Moderate

Regular formoterol and ICS vs same‐dose ICS

Non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality

Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (high certainty).

1 finding from 1 review

Inhaled steroids with and without regular formoterol for asthma: serious adverse events 2019 · Cochrane Headline outcomes only
OR 1 [0.87, 1.16]
32 studies · 35751 participants
High

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (low certainty).

1 finding from 1 review

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an… 2021 · Cochrane Headline outcomes only
OR 7.45 [0.15, 375.68]
1 study · 229 participants
Low

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).

1 finding from 1 review

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an… 2021 · Cochrane Headline outcomes only
OR 1.14 [0.82, 1.59]
7 studies · 5935 participants
Moderate

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/mometasone… compared with salmeterol/ICS (moderate certainty).

1 finding from 1 review

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an… 2021 · Cochrane Headline outcomes only
OR 1.02 [0.47, 2.2]
2 studies · 1126 participants
Moderate

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone… compared with salmeterol/ICS (low certainty).

1 finding from 1 review

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an… 2021 · Cochrane Headline outcomes only
OR 0.05 [0, 3.1]
2 studies · 293 participants
Low

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal SAE ‐ Adults · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐… compared with salmeterol/ICS (moderate certainty).

1 finding from 1 review

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an… 2021 · Cochrane Headline outcomes only
OR 0.94 [0.43, 2.08]
6 studies · 1941 participants
Moderate